Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=400&ordering=end_effective
{ "count": 2329, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=420&ordering=end_effective", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=380&ordering=end_effective", "results": [ { "id": 1510, "title": { "de": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials", "en": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials" }, "short": "IMPPACT", "url": null, "abstract": { "de": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention.", "en": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention." }, "begin_planned": "2008-06-01T02:00:00+02:00", "begin_effective": "2008-09-01T02:00:00+02:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2008-04-09T17:00:52+02:00", "program": 24, "subprogram": null, "organization": 14073, "category": 10, "type": 10, "partner_function": 2, "manager": 50874, "contact": 50874, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1510-50874-10", "1510-62118-12", "1510-51955-12", "1510-51983-12" ] }, { "id": 2550, "title": { "de": "Endothelin und Matrixmetalloproteinasen im ersten Schwangerschaftstrimester", "en": "Endothelin and matrix metalloproteinases in the first trimester of pregnancy" }, "short": "EndothelMatrix", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-08-01T02:00:00+02:00", "begin_effective": "2011-08-01T02:00:00+02:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2011-08-02T14:12:12+02:00", "program": null, "subprogram": null, "organization": 14038, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1002, "title": { "de": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials", "en": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials" }, "short": "EuroSTEC", "url": null, "abstract": { "de": "The aim of this project is to use modern tissue engineering approaches to treat children with structural disorders present at birth, such as spina bifida, urogenital defects or abdominal wall defects and surrounding anomalies. The project strives to elucidate underlying mechanisms and take a translational route through in vitro and animal experiments.\r\nThis project will give more insight in the opportunities for advanced technical possibilities with tissue engineering techniques and new treatment strategies for severe and major structural congenital birth defects in children. \r\n", "en": "The aim of this project is to use modern tissue engineering approaches to treat children with structural disorders present at birth, such as spina bifida, urogenital defects or abdominal wall defects and surrounding anomalies. The project strives to elucidate underlying mechanisms and take a translational route through in vitro and animal experiments.\r\nThis project will give more insight in the opportunities for advanced technical possibilities with tissue engineering techniques and new treatment strategies for severe and major structural congenital birth defects in children. \r\n" }, "begin_planned": "2006-11-01T01:00:00+01:00", "begin_effective": "2007-01-01T01:00:00+01:00", "end_planned": "2011-10-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2007-01-15T14:22:41+01:00", "program": 21, "subprogram": null, "organization": 14049, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2023, "title": { "de": "Induction of immunological changes by endoluminal photodynamic therapy (PDT) for esophageal carcinoma", "en": "Induction of immunological changes by endoluminal photodynamic therapy (PDT) for esophageal carcinoma" }, "short": "PDT_ESOPHAGEAL_CARCINOMA", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2009-12-18T12:29:42+01:00", "program": 79, "subprogram": null, "organization": 14077, "category": 10, "type": 10, "partner_function": 4, "manager": 51615, "contact": 51615, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2023-62056-12", "2023-51615-10", "2023-51618-12" ] }, { "id": 2092, "title": { "de": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome", "en": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome" }, "short": "GERMLINE POLYMORPH VEGF/VEGFR", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2010-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-09T11:47:57+01:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 59304, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 894 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2092-59304-10", "2092-58814-12" ] }, { "id": 1868, "title": { "de": "Computer-based analysis of heart rate variability (HRV) during different methods of acupuncture", "en": "Computer-based analysis of heart rate variability (HRV) during different methods of acupuncture" }, "short": "HRV during acupuncture", "url": null, "abstract": { "de": "Die Herzratenvariabilität stellt die prozentuelle Änderung aufeinander folgender Kammerkomplexe im EKG dar. Der Parameter HRV wird durch das Blutdruckkontrollsystem, Einflüsse vom Hypothalamus und vor allem durch den vagalen Teil des Kreislaufzentrums im unteren Hirnstamm vermittelt. Eine computergestützte Analyse der HRV soll während unterschiedlicher Methoden der Akupunktur und anderer Stimulationsmethoden im gegenständlichen Projekt zum Einsatz kommen. Für die Untersuchungen soll ein Medilog AR 12 verwendet werden. Insgesamt sollen 80 Probanden (im Alter 20-50 Jahren) während unterschiedlicher Akupunktursitzungen (Nadel- und Laserakupunktur) untersucht werden. Dabei werden die folgenden Akupunkturpunkte verwendet: Neiguan (Pe.6), Shenmen (He.7) und Hegu (Di.4). Innerhalb dieses Projektes soll die HRV auch während Stimulationen des Punktes Yintang (Ex.1) näher untersucht werden. Das Projekt könnte dazu beitragen, die Beziehungen zwischen westlicher und östlicher Medizin zu vertiefen.", "en": "Die Herzratenvariabilität stellt die prozentuelle Änderung aufeinander folgender Kammerkomplexe im EKG dar. Der Parameter HRV wird durch das Blutdruckkontrollsystem, Einflüsse vom Hypothalamus und vor allem durch den vagalen Teil des Kreislaufzentrums im unteren Hirnstamm vermittelt. Eine computergestützte Analyse der HRV soll während unterschiedlicher Methoden der Akupunktur und anderer Stimulationsmethoden im gegenständlichen Projekt zum Einsatz kommen. Für die Untersuchungen soll ein Medilog AR 12 verwendet werden. Insgesamt sollen 80 Probanden (im Alter 20-50 Jahren) während unterschiedlicher Akupunktursitzungen (Nadel- und Laserakupunktur) untersucht werden. Dabei werden die folgenden Akupunkturpunkte verwendet: Neiguan (Pe.6), Shenmen (He.7) und Hegu (Di.4). Innerhalb dieses Projektes soll die HRV auch während Stimulationen des Punktes Yintang (Ex.1) näher untersucht werden. Das Projekt könnte dazu beitragen, die Beziehungen zwischen westlicher und östlicher Medizin zu vertiefen." }, "begin_planned": "2009-10-01T02:00:00+02:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-09-30T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2009-07-13T18:54:46+02:00", "program": 79, "subprogram": null, "organization": 14044, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1868-54121-12" ] }, { "id": 2365, "title": { "de": "Plasmakonzentration und genetische Polymorphismen von PCSK9 in Patienten mit koronarer Herzkrankheit", "en": "Plasma concentration and polymorphisms of PCSK9 in patients with coronary artery disease " }, "short": "PCSK9", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-01-01T01:00:00+01:00", "begin_effective": "2011-01-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2010-12-20T12:47:35+01:00", "program": 79, "subprogram": null, "organization": 14028, "category": 10, "type": 10, "partner_function": 4, "manager": 50886, "contact": 50886, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2365-50886-10" ] }, { "id": 2504, "title": { "de": "Subtyp-spezifische, nicht kompetitive metabotrope Glutamatrezeptor-1 Antoagonisten als neuer alternativer Therapieansatz bei neuroendokrinen Tumoren", "en": "Subtype-specific, non competitive metabotropic glutamatereceptor-1 antagonists as novel alternative therapeutic option for neuroendocrine tumors" }, "short": "glutamate-receptor-1 antagonists", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-06-21T11:36:12+02:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2418, "title": { "de": "Uveales Melanom: Bio-psycho-soziale Aspekte", "en": "Uveal melanoma: Bio-psyco-social aspects " }, "short": "UVEAL MELANOMA_BIO_PSYCHO_SOCIAL_ASPECTS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-06-01T02:00:00+02:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-02-17T11:06:13+01:00", "program": null, "subprogram": null, "organization": 14043, "category": 10, "type": 10, "partner_function": 4, "manager": 61522, "contact": 61522, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 938 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2418-61522-10" ] }, { "id": 2379, "title": { "de": "Die Bedeutung der Th9-Achse bei Psoriasis ", "en": "The role of Th9 in psoriasis" }, "short": "TH9_PSORIASIS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-01-17T10:12:57+01:00", "program": null, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 51618, "contact": 51618, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 1161 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2379-51618-10" ] }, { "id": 2382, "title": { "de": "INTEROZEPTION KARDIALER AKTIVITÄT, STRESS-REAKTIVITÄT UND ATOPISCHE DERMATITIS", "en": "CARDIAC AWARENESS, STRESS REACTIVITY AND ATOPIC DERMATITIS" }, "short": "CARDIAC AWARE STRESS REACT ATOPIC DERMAT", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-02-01T01:00:00+01:00", "end_effective": "2012-02-01T01:00:00+01:00", "assignment": "2011-01-19T15:03:26+01:00", "program": null, "subprogram": null, "organization": 29447, "category": 10, "type": 10, "partner_function": 4, "manager": 60040, "contact": 60040, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2382-60040-10" ] }, { "id": 1821, "title": { "de": "Nano-Health: Nano-Plaque-Extension", "en": "Nano-Health: Nano-Plaque-Extension" }, "short": "Nano-Plaque-Extension", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-01-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T13:05:25+02:00", "program": null, "subprogram": "Nano-Health Verlängerung", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1821-52854-10" ] }, { "id": 2529, "title": { "de": "Untersuchung der MMP Expression in der humanen Chordomzellinie MUG-Chor 1", "en": "MMP Expression Analysis on the Human Chordoma Cell Line MUG-Chor 1" }, "short": "MMP EXPRESSION ANALYSIS_CHORDOMA CELL", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-10-01T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-07-14T11:48:32+02:00", "program": null, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": 50696, "contact": 50696, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2529-50696-10" ] }, { "id": 1716, "title": { "de": "Nano-Health: Nano-structured materials for drug targeting, release and imaging", "en": "Nano-Health: Nano-structured materials for drug targeting, release and imaging" }, "short": "NANO-HEALTH", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-14T14:15:30+01:00", "program": null, "subprogram": "Nano-Initiative", "organization": 28392, "category": 10, "type": 10, "partner_function": 2, "manager": 54033, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1716-54033-10" ] }, { "id": 2414, "title": { "de": "Rolle des enterischen Nervensystems (ENS) auf die Chemotaxis von Leukozyten in der Entzuendung", "en": "Chemoattraction of leukocytes by the enteric nervous system (ENS) during inflammation" }, "short": "CHEMOATTR_LEUKOCYTES_ENS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-11-01T01:00:00+01:00", "begin_effective": "2011-03-01T01:00:00+01:00", "end_planned": "2011-10-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-02-17T09:32:46+01:00", "program": null, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 56687, "contact": 56687, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 530 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2414-56687-10" ] }, { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] }, { "id": 2495, "title": { "de": "Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum", "en": "Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum" }, "short": "Bipolar affektive Erkrankungen", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-05-01T02:00:00+02:00", "begin_effective": "2011-06-01T02:00:00+02:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-06-10T12:18:59+02:00", "program": null, "subprogram": null, "organization": 29444, "category": 10, "type": 10, "partner_function": 4, "manager": 50654, "contact": 50654, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2495-50654-10" ] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": 53900, "contact": 53900, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1820-53900-10" ] }, { "id": 2496, "title": { "de": "Einfluss mechanischer Belastung auf die Expression von Matrix Metalloproteasen in Knorpelzellen aus der kindlichen Wachstumsfuge", "en": "Influence of mechanical strain on the expression of Matrix Metalloproteases in chondrocytes from the infant growth plate" }, "short": "KINDLICHE WACHSTUMSFUGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-06-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-06-10T12:21:53+02:00", "program": null, "subprogram": null, "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] } ] }